Ocean Biomedical, Inc. financial data

Symbol
OCEA
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 15 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4% % -36%
Debt-to-equity -101% % 2.3%
Return On Equity 32% % -16%
Return On Assets -2248% % -123%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 166,010,805 shares 379%
Common Stock, Shares, Outstanding 166,010,805 shares 377%
Entity Public Float $5,473,916 USD 547391452%
Weighted Average Number of Shares Outstanding, Basic 91,024,268 shares 233%
Weighted Average Number of Shares Outstanding, Diluted 91,024,268 shares 233%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $18,000 USD -31%
General and Administrative Expense $4,143,000 USD -18%
Operating Income (Loss) $4,161,000 USD 23%
Nonoperating Income (Expense) $26,558,000 USD -11%
Net Income (Loss) Attributable to Parent $30,719,000 USD -4.6%
Earnings Per Share, Basic -1 USD/shares 6.2%
Earnings Per Share, Diluted -1 USD/shares 6.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $1,492,000 USD -17%
Assets $1,582,000 USD -46%
Accounts Payable, Current $16,387,000 USD -2.9%
Liabilities, Current $26,568,000 USD -12%
Liabilities $93,981,000 USD 19%
Retained Earnings (Accumulated Deficit) $213,775,000 USD -17%
Stockholders' Equity Attributable to Parent $92,399,000 USD -22%
Liabilities and Equity $1,582,000 USD -46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $356,000 USD 27%
Net Cash Provided by (Used in) Financing Activities $909,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 166,010,805 shares 377%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $553,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $800,000 USD
Deferred Tax Assets, Valuation Allowance $22,592,000 USD 8.8%
Deferred Tax Assets, Gross $22,592,000 USD 8.8%
Deferred Tax Assets, Operating Loss Carryforwards $7,642,000 USD 28%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $121,376,000 USD 13%
Share-based Payment Arrangement, Expense $745,000 USD 0%